Rare Antidote ‘BabyBIG’ Offers Hope Amidst Infant Botulism Outbreak Linked to ByHeart Formula
Table of Contents
A life-saving treatment, developed over decades and reliant on a small pool of dedicated donors, is proving critical in combating a recent surge of infant botulism cases linked to contaminated baby formula.
The outbreak, connected to ByHeart infant formula, has sickened at least 39 babies across 18 U.S. states since August, highlighting the vital role of BabyBIG, a human botulinum immunoglobulin. This intravenous medication utilizes antibodies from vaccinated volunteers to combat the debilitating and potentially fatal illness.
The Silent Threat of Infant Botulism
Infant botulism is a rare but serious condition occurring when babies ingest botulism spores, which then germinate in their intestines and produce a dangerous toxin. This toxin attacks the nervous system, leading to muscle weakness and potentially paralysis. Prior to the development of BabyBIG, hospitalizations could last for months, even if the child ultimately recovered.
“It’s almost a miracle,” said a pediatric neurologist at Children’s Hospital Los Angeles, who has treated multiple cases of botulism, including one during the current outbreak. “Before the discovery of BabyBIG, some hospitalizations lasted two or three months.”
A Legacy of Scientific Dedication
The creation of BabyBIG is largely attributed to the late Dr. Stephen Arnon, a scientist with the California Department of Public Health. In 1976, Dr. Arnon and his team identified the specific form of botulism affecting infants under one year old, and he subsequently dedicated 45 years to finding an effective treatment. A landmark clinical trial in California in 1997 demonstrated that BabyBIG could significantly shorten hospital stays and reduce the need for ventilators.
To date, more than 3,700 children worldwide have benefited from the treatment. However, the drug is produced in small batches – only every five years – and comes at a substantial cost, nearly $70,000 per treatment, according to the California Infant Botulism Treatment and Prevention Program, which Dr. Arnon founded. Revenues generated from drug sales are legally mandated to be reinvested into the botulism program.
The Power of Volunteer Donors
BabyBIG’s production relies entirely on the generosity of volunteer donors, individuals who have been vaccinated against botulism and possess high levels of neutralizing antibodies in their blood plasma. One such donor is Nancy Shine, a 76-year-old retired biochemist from California.
Shine was initially recruited by Dr. Arnon two decades ago due to her background working with the deadly germ in a laboratory setting. While the process of donating plasma involved receiving booster doses of an experimental vaccine and experiencing side effects like blisters and pain, Shine considers it a profound contribution. “It’s probably the highlight of my career to be able to participate in this project and donate plasma,” she said. “We have designed a product that can save the lives of infants.”
Challenges and Future Outlook
Developing BabyBIG was not without its hurdles. Due to the rarity of infant botulism – fewer than 200 cases are reported annually in the U.S. – securing funding and resources took nearly 15 years and $10.6 million. Currently, approximately 30 people contribute plasma for each batch of BabyBIG, with Batch 8 currently being manufactured by Takeda Pharmaceutical Co. near Los Angeles on a “not-for-profit” basis.
The program is facing a challenge as some of the original donors, like Shine, are now over the age limit of 70. New donors are being sought, but must enroll in a clinical study and receive another experimental botulism vaccine. Despite these challenges, California health officials estimate they have enough BabyBIG in reserve to last until next summer.
The current outbreak linked to ByHeart formula coincides with a broader increase in infant botulism cases, with at least 107 cases treated in the U.S. since August, according to a senior medical officer for the state program. The impact of BabyBIG is deeply felt by families like that of Alessandro Barbera, whose father expressed immense gratitude for the treatment that is aiding his son’s recovery.
Shine recently received a booklet filled with photos and letters from families whose children were saved by BabyBIG. “It’s really wonderful. I read a few every day,” she said. “Every one of them makes you want to cry.”